Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05178966
Other study ID # 2021-A01317-34
Secondary ID 2021-A01317-34
Status Recruiting
Phase N/A
First received
Last updated
Start date November 9, 2022
Est. completion date May 31, 2024

Study information

Verified date November 2022
Source University Hospital, Montpellier
Contact Kathlyne DUPUIS MAURIN
Phone +33467335663
Email k-dupuis@chu-montpellier.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Bipolar disorder (BD) has a huge impact on the lives of patient and their relatives. Psychoeducation programs on BD has been shown to be effective on the burden of patients and their caregivers. However, actual programs appear to be incompatible with patients obligations and services requirements of the service. The development of "minute" programs (in one day) is justified.


Description:

Bipolar disorder (BD) has a huge impact on patient lives and their relatives. BD psychoeducation has been shown to be effective on patient disease course and caregivers burden. However, the programs offered appear to be incompatible with the participants obligations and services requirements. In this context we wanted to develop a "minute" program (Bp one day). Study participation includes 3 visits : inclusion visit and 2 follow up visits. The main objective is to assess the effectiveness of day psychoeducational program (BP OneDay) on caregiver burden at one month according to the Zarit Caregiver Burden Interview (ZCBI) total score. This study also aims to assess the effectiveness of BP OneDay on caregiver stigma, patient self-stigma and medication adherence, quality of life, and bipolar disorder knowledge. The study is an open-label randomized controlled trial with two arms Overall, 120 dyads will be recruited randomly affected in 2 groups : - the interventional group will benefit from a day psychoeducational program : Bp oneDay - the control group will be placed on the waiting list The benefits expected from Bp OneDay are to reduce caregiver burden and stigma and improve knowledge about BD. For patients, we expect improve disease understanding, drug adherence and reduce self-stigmatization. If the results are promising, this program can be widely disseminated and thus increase cares' solution for patients and relatives in large urban centers.


Recruitment information / eligibility

Status Recruiting
Enrollment 240
Est. completion date May 31, 2024
Est. primary completion date May 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Patient inclusion Criteria: - Be over 18 years old; - Meet the criteria for bipolar disorder (I, II, unspecified) according to the DSM-5 criteria; - Be able to understand the nature, purpose and methodology of the study; - Presence of a caregiver Patient Exclusion Criteria: - Subject unable to adhere to the group requirements (cognitive disorder, decompensated mood state ...); - Subject protected by law (subject under guardianship and / or guardianship) or deprived of liberty by a judicial or administrative decision; - Subject unable to understand, speak and write French; - Subject in a period of exclusion from another protocol. - Subject not having signed an informed consent - Subject not affiliated with a social security scheme or such a scheme Caregiver inclusion criteria ; - Subject over 18 years old; - Subject designated as a regular caregiver of a patient with bipolar disorder. A regular caregiver is a trusted person designated by the patient as being one of his main support, having knowledge of the diagnosis of bipolar disorder and who can be called upon in the context of care. - Subject able to understand the nature, purpose and methodology of the study; Caregiver exclusion criteria : - Subject unable to adhere to the groupre quirements (cognitive disorder, decompensated mood state ...); - Subject protected by law (subject under guardianship and / or curatorship) or deprived of liberty by a judicial or administrative decision ; - Subject unable to understand, speak and write French; - Subject in a period of exclusion from another protocol. - Subject not having signed an informed consent - Subject not affiliated with a social security scheme or such a scheme

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Bp OneDay psychoeducation program
The BP One-Day Psychoeducation program is based on a single day of psychoeducation . This program was carried out by members of the bipolar expert center network in various hospitals of the network and included : Representation of BD Definition, diagnosis and awareness of the disorder Depressive, hypo / manic symptoms Vulnerability to BD causes of BD, risk factors for relapses Drug treatments, drug compliance and non-drug treatments Early detection of prodromal signs Communication techniques Each BP One-Day psychoeducation session welcomes an average of ten participants (5 patients / 5 caregivers). At the end of the day, participants receive a booklet containing the main information of the day. BP One-Day program is delivered by a nurse and a psychologist specialized in both BD and therapy group facilitation. A specialized psychiatrist intervenes in the section "Medication treatments and medication adherence" for a period of approximately one hour.

Locations

Country Name City State
France University Hospital of Montpellier Montpellier

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary caregivers burden evaluation of caregiver burden based on the Zarit Caregiver Burden Interview total score.
The Zarit Caregiver Burden Interview is a self-administered questionnaire assessing caregiver burden using 22 items. Five themes are examined: psychological and physical suffering, financial, relational and social difficulties. For each of the 22 items, the caregiver determines how often he feels a given emotion in the helping relationship. This frequency ranges from 0 "never" to 4 "Almost always". The overall score is obtained by adding all the items together, it varies from 0 to 88. The higher the score, the greater the burden felt by the caregiver.
Day65 for experimental group, Day35 for control group
Secondary caregivers stigmatization évaluation of caregivers stigmatization using Affiliate stigma scale on caregivers of people with mental illness The Affiliate stigma scale on caregivers of people with mental illness is a self-questionnaire composed of 22 items assessing 3 dimensions of stigma : the cognitive, affective and behavioral dimension. Participants are asked to rate their level of agreement with the statements on a 4-point Likert scale (ranging from 1 "Strongly disagree" to 4 "Strongly agree). The total score ranges from 22 to 88. The higher the score, the more severe the stigma. Day44 for experimental group, Day14 for control group
Secondary caregivers stigmatization évaluation of caregivers stigmatization using Affiliate stigma scale on caregivers of people with mental illness The Affiliate stigma scale on caregivers of people with mental illness is a self-questionnaire composed of 22 items assessing 3 dimensions of stigma : the cognitive, affective and behavioral dimension. Participants are asked to rate their level of agreement with the statements on a 4-point Likert scale (ranging from 1 "Strongly disagree" to 4 "Strongly agree). The total score ranges from 22 to 88. The higher the score, the more severe the stigma. Day65 for experimental group, Day35 for control group
Secondary Internalized Stigma of patients evaluation of Internalized Stigma according to the Internalized Stigma of Mental Illness total score This self-questionnaire consists of 29 items. Each item is rated using a 4-points Likert scale ranging from 1 "Strongly disagree" to 4 "Strongly agree". The 29 items are grouped according to 5 themes: alienation (the fact of not feeling a full member of the society in which we live), approval of stereotypes, perceived discrimination, social withdrawal, and resistance to stigma. The higher the score, the more severe the self-stigma. Day44 for experimental group, Day14 for control group
Secondary Internalized Stigma of patients evaluation of Internalized Stigma according to the Internalized Stigma of Mental Illness total score This self-questionnaire consists of 29 items. Each item is rated using a 4-points Likert scale ranging from 1 "Strongly disagree" to 4 "Strongly agree". The 29 items are grouped according to 5 themes: alienation (the fact of not feeling a full member of the society in which we live), approval of stereotypes, perceived discrimination, social withdrawal, and resistance to stigma. The higher the score, the more severe the self-stigma. Day65 for experimental group, Day35 for control group
Secondary Patient quality of life Evaluation of patient quality of life according to the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form total score.
This 16-items self-administered questionnaire assesses the quality of life through the assessment of physical health, social relationships, family relationships, mood, libido, the ability to function on a daily basis, the ability to invest and enjoy leisure time, to work, the economic level, the place of life and the general feeling of well-being. The last two items assess satisfaction with treatment as well as satisfaction with life and are treated independently of the others. Each item is scored on a 5-point Likert scale and represents the level of satisfaction experienced over the last week. A calculation of the overall score is performed for items 1 to 14 (ranging from 14 to 70) and is expressed as a percentage (0-100). The higher the score, the better the quality of life.
Day44 for experimental group, Day14 for control group
Secondary Patient quality of life Evaluation of patient quality of life according to the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form total score.
This 16-items self-administered questionnaire assesses the quality of life through the assessment of physical health, social relationships, family relationships, mood, libido, the ability to function on a daily basis, the ability to invest and enjoy leisure time, to work, the economic level, the place of life and the general feeling of well-being. The last two items assess satisfaction with treatment as well as satisfaction with life and are treated independently of the others. Each item is scored on a 5-point Likert scale and represents the level of satisfaction experienced over the last week. A calculation of the overall score is performed for items 1 to 14 (ranging from 14 to 70) and is expressed as a percentage (0-100). The higher the score, the better the quality of life.
Day65 for experimental group, Day35 for control group
Secondary caregivers quality of life Evaluation of caregivers quality of life according to the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form total score.
This 16-items self-administered questionnaire assesses the quality of life through the assessment of physical health, social relationships, family relationships, mood, libido, the ability to function on a daily basis, the ability to invest and enjoy leisure time, to work, the economic level, the place of life and the general feeling of well-being. The last two items assess satisfaction with treatment as well as satisfaction with life and are treated independently of the others. Each item is scored on a 5-point Likert scale and represents the level of satisfaction experienced over the last week. A calculation of the overall score is performed for items 1 to 14 (ranging from 14 to 70) and is expressed as a percentage (0-100). The higher the score, the better the quality of life.
Day44 for experimental group, Day14 for control group
Secondary caregivers quality of life Evaluation of caregivers quality of life according to the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form total score.
This 16-items self-administered questionnaire assesses the quality of life through the assessment of physical health, social relationships, family relationships, mood, libido, the ability to function on a daily basis, the ability to invest and enjoy leisure time, to work, the economic level, the place of life and the general feeling of well-being. The last two items assess satisfaction with treatment as well as satisfaction with life and are treated independently of the others. Each item is scored on a 5-point Likert scale and represents the level of satisfaction experienced over the last week. A calculation of the overall score is performed for items 1 to 14 (ranging from 14 to 70) and is expressed as a percentage (0-100). The higher the score, the better the quality of life.
Day65 for experimental group, Day35 for control group
Secondary Medication Adherence Evaluation of patient medication adherence according to Medication Adherence Rating Scale total score.
This self-questionnaire has 10 yes / no items. The total score varies between 0 and 10. The higher the score, the better the compliance. This scale was created and is widely used in the psychiatric population.
Day44 for experimental group, Day14 for control group
Secondary Medication Adherence Evaluation of patient medication adherence according to Medication Adherence Rating Scale total score.
This self-questionnaire has 10 yes / no items. The total score varies between 0 and 10. The higher the score, the better the compliance. This scale was created and is widely used in the psychiatric population.
Day65 for experimental group, Day35 for control group
Secondary Bipolar disorder Knowledge in patients Evaluation of Bipolar Disorde knowledge in patients according to "Quizz BP" total score.
This self-administered questionnaire is composed of twenty true or false questions. It addresses different themes: occurrence, etiology, semiology, factors triggering episodes, comorbidities, treatments. The overall score fluctuates between 0 and 20. Although this test has not been validated, it has already been used in several published works
Day44 for experimental group, Day14 for control group
Secondary Bipolar disorder Knowledge in patients Evaluation of Bipolar Disorde knowledge in patients according to "Quizz BP" total score.
This self-administered questionnaire is composed of twenty true or false questions. It addresses different themes: occurrence, etiology, semiology, factors triggering episodes, comorbidities, treatments. The overall score fluctuates between 0 and 20. Although this test has not been validated, it has already been used in several published works
Day65 for experimental group, Day35 for control group
Secondary Bipolar disorder Knowledge in caregivers Evaluation of Bipolar Disorde knowledge in caregivers according to "Quizz BP" total score.
This self-administered questionnaire is composed of twenty true or false questions. It addresses different themes: occurrence, etiology, semiology, factors triggering episodes, comorbidities, treatments. The overall score fluctuates between 0 and 20. Although this test has not been validated, it has already been used in several published works
Day44 for experimental group, Day14 for control group
Secondary Bipolar disorder Knowledge in caregivers Evaluation of Bipolar Disorde knowledge in caregivers according to "Quizz BP" total score.
This self-administered questionnaire is composed of twenty true or false questions. It addresses different themes: occurrence, etiology, semiology, factors triggering episodes, comorbidities, treatments. The overall score fluctuates between 0 and 20. Although this test has not been validated, it has already been used in several published works
Day65 for experimental group, Day35 for control group
Secondary Patient satisfaction Evaluation of patient satisfaction with the group according to a liker score ranged from 0 "absolutely not satisfied" to 10 "Extremely satisfied" Day44 for experimental group, Day14 for control group
Secondary caregiver satisfaction Evaluation of caregiver satisfaction with the group according to a liker score ranged from 0 "absolutely not satisfied" to 10 "Extremely satisfied" Day44 for experimental group, Day14 for control group
See also
  Status Clinical Trial Phase
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT02855762 - Targeting the Microbiome to Improve Clinical Outcomes in Bipolar Disorder N/A
Recruiting NCT05915013 - Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response Phase 1
Recruiting NCT05206747 - Ottawa Sunglasses at Night for Mania Study N/A
Completed NCT02513654 - Pharmacokinetics, Safety and Tolerability of Repeat Dosing Lamotrigine in Healthy Chinese Subjects Phase 1
Recruiting NCT06313918 - Exercise Therapy in Mental Disorders-study N/A
Completed NCT02304432 - Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine Early Phase 1
Recruiting NCT06197048 - Effect of Nutritional Counseling on Anthropometry and Biomarkers in Patients Diagnosed With Schizophrenia/Psychosis or Bipolar Affective Disorder N/A
Completed NCT03497663 - VIA Family - Family Based Early Intervention Versus Treatment as Usual N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Completed NCT02212041 - Electronic Cigarettes in Smokers With Mental Illness N/A
Recruiting NCT05030272 - Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings N/A
Recruiting NCT04298450 - ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention N/A
Active, not recruiting NCT03641300 - Efficacy of Convulsive Therapies for Bipolar Depression N/A
Not yet recruiting NCT04432116 - Time and Virtual Reality in Schizophrenia and Bipolar Disorder N/A
Terminated NCT02909504 - Gao NARASD Lithium Study Phase 4
Terminated NCT02893371 - Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
Completed NCT02970721 - Use of Psychotropic Medications Among Pregnant Women With Bipolar Disorder
Recruiting NCT03088657 - Design and Methods of the Mood Disorder Cohort Research Consortium (MDCRC) Study
Recruiting NCT02481245 - BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study Phase 2